{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:42:29Z","timestamp":1789756949971,"version":"4.0.1"},"reference-count":70,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To review the mechanism of action, development, and clinical application of the calcimimetic compounds being investigated for the treatment of primary and secondary hyperparathyroidism (HPT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES<\/jats:title>\n                    <jats:p>A MEDLINE search (1990\u2013April 2004) was performed to identify all published articles related to calcimimetics. Published abstracts over the previous 5 years from various scientific meetings (American Society of Nephrology, American Society for Clinical Pharmacology and Therapeutics, American Society of Bone and Mineral Research) were also searched for reports regarding investigational calcimimetic agents. Data on cinacalcet HCI were provided by Amgen, Inc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION<\/jats:title>\n                    <jats:p>Studies were selected based on number of patients included, relevance to the approved indications, and inclusion of pharmacokinetic and drug interaction information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS<\/jats:title>\n                    <jats:p>The investigational calcimimetic compounds directly modulate the calcium-sensing receptor and can produce at least a 30% reduction in parathyroid hormone (PTH) secretion in secondary HPT. Cinacalcet appears to have more predictable pharmacokinetics and a lower risk of symptomatic hypocalcemia than the older agent, R-568. The safety profile and effective reduction in PTH and simultaneous reductions in calcium and phosphorus (and the calcium\u2013phosphorus product) induced by cinacalcet make this agent advantageous over previously used therapies, such as vitamin D and phosphate-binding agents. More studies are required to determine additional uses of cinacalcet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Cinacalcet has a unique mechanism for reducing PTH concentration and appears to be a safe and effective oral therapy for both primary and secondary HPT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1d108","type":"journal-article","created":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T21:33:50Z","timestamp":1097616830000},"page":"1871-1880","source":"Crossref","is-referenced-by-count":31,"title":["Calcimimetics and the Treatment of Primary and Secondary Hyperparathyroidism"],"prefix":"10.1177","volume":"38","author":[{"given":"Melanie S","family":"Joy","sequence":"first","affiliation":[{"name":"Melanie S Joy PharmD, Associate Professor, Division of Nephrology and Hypertension, School of Medicine, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit V","family":"Kshirsagar","sequence":"additional","affiliation":[{"name":"Abhijit V Kshirsagar MD MPH, Assistant Professor, Division of Nephrology and Hypertension, School of Medicine, University of North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Franceschini","sequence":"additional","affiliation":[{"name":"Nora Franceschini MD, Instructor, Division of Nephrology and Hypertension, School of Medicine, University of North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2004,11,1]]},"reference":[{"key":"bibr1-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.057273"},{"key":"bibr2-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07304.x"},{"key":"bibr3-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330307"},{"key":"bibr4-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.suppl_4.43"},{"key":"bibr5-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100309"},{"key":"bibr6-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200101000-00007"},{"key":"bibr7-aph.1D108","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/jbmr.5650061406","volume":"6","author":"Potts JT","year":"1991","journal-title":"J Bone Miner Res"},{"key":"bibr8-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411701"},{"key":"bibr9-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"bibr10-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70064-3"},{"key":"bibr11-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12102131"},{"key":"bibr12-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01781-8"},{"key":"bibr13-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422003"},{"key":"bibr14-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.8.2037"},{"key":"bibr15-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(00)00031-5"},{"key":"bibr16-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1991.71.2.371"},{"key":"bibr17-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1038\/366575a0"},{"key":"bibr18-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.1.131"},{"key":"bibr19-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.5.1167"},{"key":"bibr20-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.21.12919"},{"key":"bibr21-aph.1D108","first-page":"1083","volume":"53","author":"Hammerland LG","year":"1998","journal-title":"Mol Pharmacol"},{"key":"bibr22-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1210\/endo.136.11.7588259"},{"key":"bibr23-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009317200"},{"key":"bibr24-aph.1D108","first-page":"555","volume":"10","author":"Emanuel RL","year":"1996","journal-title":"Mol Endocrinol"},{"key":"bibr25-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1997.273.4.C1168"},{"key":"bibr26-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.36.23344"},{"key":"bibr27-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.8.3161"},{"key":"bibr28-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.29.20561"},{"key":"bibr29-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukaryotGeneExpr.v13.i24.30"},{"key":"bibr30-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00183.x"},{"key":"bibr31-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00837.x"},{"key":"bibr32-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119851"},{"key":"bibr33-aph.1D108","first-page":"473","volume":"290","author":"Fox J","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr34-aph.1D108","first-page":"480","volume":"290","author":"Fox J","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr35-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(99)00263-X"},{"key":"bibr36-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(00)00350-1"},{"key":"bibr37-aph.1D108","unstructured":"37. Martin D, Colloton M, Shatzen E, Padagas J, Campagnuolo J, Korach E, Cinacalcet HCl decreases parathyroid hormone and blood-ionized calcium in rodent models of chronic kidney disease accompanied by secondary hyperparathyroidism (abstract SA-PO749). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr38-aph.1D108","unstructured":"38. Martin D, Miller G, Colloton M, Shatzen E, Lacey D. Cinacalcet HCl decreases parathyroid hyperplasia in a rodent model of chronic kidney disease (abstract SA-PO748). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr39-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372104"},{"key":"bibr40-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00735.x"},{"key":"bibr41-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1341017"},{"key":"bibr42-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.4.4726"},{"key":"bibr43-aph.1D108","unstructured":"43. Wang B, Osborn K, Blaisdell PW, Brenner RM, Turner SA, Laycock J, Pharmacokinetics (PK) of calcimimetic AMG073 in secondary hyperparathyroidism (SHPT) (abstract PIII-103). Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 6\u201310, 2001."},{"key":"bibr44-aph.1D108","volume-title":"Package insert. Sensipar (cinacalcet HCl)","year":"2004"},{"key":"bibr45-aph.1D108","unstructured":"45. Peacock M, Shoback DM, Greth WE, Binder TA, Graves T, Brenner RM, The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT) (abstract 1106). Presented at: American Society of Bone and Mineral Research 23rd Annual Meeting, Phoenix, AZ, October 12\u201316, 2001."},{"key":"bibr46-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021597"},{"key":"bibr47-aph.1D108","unstructured":"47. Shoback DM, Firek AF, Mims RB, Binder TA, Graves T, Turner SA, The effect of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism (PHPT) (abstract SA462). Presented at: American Society of Bone and Mineral Research 23rd Annual Meeting, Phoenix, AZ, October 12\u201316, 2001."},{"key":"bibr48-aph.1D108","unstructured":"48. Coyne DW, Stegman MH, Azad H, Joy MS, Mischel SF, Pokroy N, Cinacalcet HCl controls secondary hyperparathyroidism regardless of gender, race, age, and geography in patients with chronic kidney disease receiving dialysis (abstract SA-PO754). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr49-aph.1D108","unstructured":"49. Quarles LD, Zeig S, Spiegel DM, Silver MR, Vokes TJ, Torregrosa JV, Cinacalcet HCl (AMG 073) controls secondary hyperparathyroidism in dialysis patients regardless of disease severity (abstract SA-PO751). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr50-aph.1D108","unstructured":"50. Goodman WG, Fadda GZ, Finkelstein FO, Mittman N, Lien YH, Leblanc M, Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism (abstract SA-PO741). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr51-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"bibr52-aph.1D108","unstructured":"52. Moe SM, Coburn JW, Quarles LD, Goodman WG, Chertow GM, Block GA, Achievement of proposed NKF-K\/DOQI bone metabolism and disease targets: treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism (abstract SC-FC217). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr53-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00720.x"},{"key":"bibr54-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000050224.03126.AD"},{"key":"bibr55-aph.1D108","unstructured":"55. Moe SM, Sprague SM, Cunningham J, Drueke T, Adler S, Rosansky SJ, Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl (abstract SA-PO753). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr56-aph.1D108","unstructured":"56. Block GA, Martin KJ, Turner SA, Avram MM, Hercz G, Abu-Alfa AK, Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism (abstract SA-PO743). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr57-aph.1D108","unstructured":"57. de Francisco A, Suranyi M, Cunningham J, Messa P, Locatelli F, Evenepoel P, Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism: results of a European\/Australian Phase 3 study (abstract SA-PO742). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr58-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"bibr59-aph.1D108","unstructured":"59. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Phase 3 experience with cinacalcet HCl in hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism (abstract SAPO-752). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr60-aph.1D108","unstructured":"60. Padhi D, Harris R, Salfi M, Yates W, Hansen J, Flynn J, Cinacalcet HCl absorption is not affected by coadministration of medications commonly prescribed to chronic kidney disease patients (pantoprazole sodium, sevelamer HCl, and calcium carbonate) (abstract SA-PO744). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr61-aph.1D108","unstructured":"61. Padhi D, Harris R, Salfi M, Yates W, Henday L, Hansen J, The pharmacokinetics of cinacalcet HCl are comparable in patients with chronic kidney disease receiving hemodialysis or continuous ambulatory peritoneal dialysis (abstract SA-PO745). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr62-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000056188.23717.E5"},{"key":"bibr63-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00782.x"},{"key":"bibr64-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9820463"},{"key":"bibr65-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9820470"},{"key":"bibr66-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.22"},{"key":"bibr67-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.2.218"},{"key":"bibr68-aph.1D108","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.10.1713"},{"key":"bibr69-aph.1D108","unstructured":"69. Martin D, Colloton M, Cattley R, Shatzen E, Lacey D. 1\u03b1,25-dihydroxy-vitamin D\n                      3\n                      but not cinacalcet HCl treatment mediates aortic min eralization in a rat model of secondary hyperparathyroidism (abstract SU-PO719). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."},{"key":"bibr70-aph.1D108","unstructured":"70. Coburn JW, Charytan C, Chonchol M, Herman J, Lien YH, Liu W, Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism in patients with chronic kidney disease not yet receiving dialysis (abstract SA-PO740 and poster). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12\u201317, 2003."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1D108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:57Z","timestamp":1777374477000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1D108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1345\/aph.1D108"],"URL":"https:\/\/doi.org\/10.1345\/aph.1d108","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}